Abstract
The different approaches that the International Olympic Committee (IOC) had adopted to β2-agonists and the implications for athletes are reviewed by a former Olympic team physician who later became a member of the Medical Commission of the IOC (IOC-MC). Steadily increasing knowledge of the effects of inhaled β2-agonists on health, is concerned with the fact that oral β2-agonists may be anabolic, and rapid increased use of inhaled β2-agonists by elite athletes has contributed to the changes to the IOC rules. Since 2001, the necessity for athletes to meet IOC criteria (i.e., that they have asthma and/or exercise-induced asthma [EIA]) has resulted in imporved management of athletes. The prevalence of β2-agonist use by athletes mirrors the known prevalence of asthma symptoms in each country, although athletes in endurance events have the highest prevalence. The age-of-onset of asthma/EIA in elite winter athletes may be atypical. Of the 193 athletes at the 2006 Winter Olympics who met th IOC's criteria, only 32.1% had childhood asthma and 48.7% of athletes reported onset at age 20 yr or older. These findings lead to speculation that years of intense endurance training may be a causative factor in bronchial hyperreactivity. The distinction between oral (prohibited in sports) and inhaled salbutamol is possible, but athletes must be warned that excessive use of inhaled salbutamol can lead to urinary concentrations similar to those observed after oral administration. This article provides justification that athletes should provide evidence of asthma or EIA before being permitted to use inhaled β2-agonists.
Similar content being viewed by others
References
Crane, J., Pearce, N., Flatt, A., et al. (1989), Prescribed fenoterol and death from asthma in New Zealand, 1981–83: case-control study. Lancet 1, 917–922.
Clausnitzer, C. (1985), Communication to IOC Medical Commission 18 March.
Fitch, K. D. (1986), The use of anti-asthmatic drugs. Do they affect sports performance? Sports Med. 3, 136–150.
Phillips, W. N. (1992). The secret of clenbuterol. Special Report #1. Golden, CO: Mile High Publishing.
Martineau, L., Horan, M. A., Rothwell, N. J., and Little, R. A. (1992), Salbutamol, a beta 2-adrenoceptor agonist, increases skeletal muscle strength in young men. Clin. Sci. (Lond.), 83, 615–621.
Larsson, K., Ohlsen, P., Larsson, L., Malmberg, P., Rydstrom, P. O., and Ulriksen, H. (1993), High prevalence of asthma in cross country skiers. BMJ 307, 1326–1329.
http://www.olympic.org/uk/games/torino/atue/ index_uk.asp, Accessed January 14, 2006.
Anderson, S. D., Fitch, K., Perry, C. P., et al. (2003), Responses to bronchial challenge submitted for approval to use inhaled beta2-agonists before an event at the 2002 Winter Olympics. J. Allergy Clin. Immunol. 111, 45–50.
Anderson, S. D., Sue-Chu, M., Perry, C. P., et al. (2006), Bronchial challenges in athletes applying to inhale a β2-agonist at the 2004 summer Olympics. J. Allergy Clin. Immunol. 117, 767–773.
Hancox, R. J., Subbarao, P., Kamada, D., Watson, R. M., Hargreave, F. E., and Inman, M. D. (2002), Beta2-agonist tolerance and exercise-induced bronchospasm. Am. J. Respir. Crit. Care Med. 165, 1068–1070.
Ramage, L., Lipworth, B. J., Ingram, C. G., Cree, I. A., and Dhillon, D. P. (1994), Reduced protection against exercise induced bronchoconstriction after chronic dosing with salmeterol. Respir. Med. 88, 363–368.
Storms, W., Chervinsky, P., Ghannam, A. F., Bird, S., Hustad, C. M., and Edelman, J. M. (2004), A comparison of the effects of oral montelukast and inhaled salmeterol on response to rescue bronchodilation after challenge. Respir. Med. 98, 1051–1062.
Anderson, S. D. and Brannan, J. D. (2004) Longacting beta 2-adrenoceptor agonists and exercise-induced asthma: lessons to guide us in the future. Paediatr. Drugs 6, 161–175.
Haney, S. and Hancox, R. J. (2005), Rapid onset of tolerance to beta-agonist bronchodilation. Respir. Med. 99, 566–571.
Anderson, S. D., Brusasco, V., Haahtela, T., and Popov, T. (2005), Criteria for diagnosis of asthma, exercise-induced bronchoconstriction and airway hyperesponsiveness for athlete: Lessons from the Olympic Games. In Diagnosis, Prevention and Treatment of Exercise Related Asthma, Respiratory and Allergic Disorders in Sports, Carlsen, K.-H., Delgado, L., and Del Giacco, S., eds., Eur Respir Mon. Wakefield, UK: European Respiratory Society, pp. 48–66.
Dickinson, J. W., Whyte, G. P., McConnell, A. K., and Harries, M. G. (2005), Impact of changes in the IOC-MC asthma criteria: a British perspective. Thorax 60, 629–632.
Bjermer, J. and Anderson, S. D. (2005), Bronchial hyperresponsiveness in athletes; mechanisms for development. In Diagnosis, Prevention and Treatment of Exercise Related Asthma, Respiratory and Allergic Disorders in Sports, Carlsen, K.-H., Delgado, L., and Del Giacco, S., eds., Eur Respir Mon Wakefield UK: European Respiratory Society, pp. 19–34.
Fitch, K. D., Morton, A. R., and Blanksby, B. A. (1976), Effects of swimming training on children with asthma. Arch. Dis. Child. 51, 19–194.
Drobnic, F. and Haahtela, T. (2005), The role of the environment and climate in relation to outdoor and indoor sports. In Diagnosis, Prevention and Treatment of Exercise Related Asthma, Respiratory and Allergic Disorders in Sports, Carlsen, K.-H., Delgado, L., and Del Giacco, S., eds., Eur Respir Mon. Wakefield, UK: European Respiratory Society, pp. 35–47.
(1998), Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Lancet 351, 1225–1232.
Chinn, S., Burney, P., Jarvis, D., and Luczynska, C. (1997), Variation in bronchial responsiveness in the European Community Respiratory Health Survey (ECRHS). Eur. Respir. J. 10, 2495–2501.
Fitch, K. D. (1984), Management of allergic Olympic athletes. J. Allergy Clin. Immunol. 73, 722–727.
Delbeke, F. T., Desmet, N., and Debackere, M. (1995), The abuse of doping agents in competing body builders in Flanders (1988–1993). Int. J. Sports Med. 16, 66–70.
Yang, Y. T. and McElligott, M. A. (1989), Multiple actions of beta-adrenergic agonists on skeletal muscle and adipose tissue. Biochem. J. 261, 1–10.
McKenzie, D. C., Rhodes, E. C., Stirling, D. R., et al. (1983), Salbutamol and treadmill performance in non-atopic athletes. Med. Sci. Sports Exerc. 15, 520–522.
Meeuwisse, W. H., McKenzie, D. C., Hopkins, S. R., and Road, J. D. (1992), The effect of salbutamol on performance in elite nonasthmatic athletes. Med. Sci. Sports Exerc. 24, 1161–1166.
Morton, A. R., Papalia, S. M., and Fitch, K. D. (1992), Is salbutamol ergogenic? The effects of salbutamol on physical performance in high performance nonasthmatic athletes. Clin. J Sport Med. 2, 93–97.
Heir, T. and Stemshaug, H. (1995), Salbutamol and high-intensity treadmill running in nonasthmatic highly conditioned athletes. Scand. J. Med. Sci. Sports 5, 231–236.
Morton, A. R., Joyce, K., Papalia, S. M., Carroll, N. G., and Fitch, K. D. (1996), Is salmeterol ergogenic? Clin. J. Sport Med. 6, 220–225.
Sue-Chu, M., Sandsund, M., Helgerud, J., Reinertsen, R. E., and Bjermer, L. (1999), Salmeterol and physical performance at −15 degrees C in highly trained nonasthmatic cross-country skiers. Scand. J. Med. Sci. Sports 9, 48–52.
Carlsen, K. H., Hem, E., Stensrud, T., Held, T., Herland, K., and Mowinckel, P. (2001), Can asthma treatment in sports be doping? The effect of the rapid onset, long-acting inhaled beta2-agonist formoterol upon endurance performance in healthy well-trained athletes. Respir. Med. 95, 571–576.
Stewart, I. B., Labreche, J. M., and McKenzie, D. C. (2002), Acute formoterol administration has no ergogenic effect in nonasthmatic athletes. Med. Sci. Sports Exerc. 34, 213–217.
Larsson, K., Gavhed, D., Larsson, L., Holmer, I., Jorfelt, L., and Ohlsen, P. (1997), Influence of a beta2-agonist on physical performance at low temperature in elite athletes. Med. Sci. Sports Exerc. 29, 1631–1636.
Collomp, K., Candau, R., Lasne, F., Labay, Z., Prefaut, C., and De Ceaurriz, J. (2000), Effects of short-term oral salbutamol administration on exercise endurance and metabolism. J. Appl. Physiol. 89, 430–436.
Caruso, J. F., Signorile, J. F., Perry, A. C., et al. (1995), The effects of albuterol and isokinetic exercise on the quadriceps muscle group. Med. Sci. Sports Exerc. 27, 1471–1476.
Caruso, J. F., Hamill, J. L., and De Garmo, N. (2005), Oral albuterol dosing during the latter stages of a resistance exercise program. J. Strength Cond. Res. 19, 102–107.
van Baak, M. A., Mayer, L. H., Kempinski, R. E., and Hartgens, F. (2000), Effect of salbutamol on muscle strength and endurance performance in nonasthmatic men. Med. Sci. Sports Exerc. 32, 1300–1306.
Collomp, K., Le Panse, B., Portier, H., et al. (2005), Effects of acute salbutamol intake during a Wingate test. Int. J. Sports Med. 26, 513–517.
Ventura, R., Segura, J., Berges, R., et al. (2000), Distinction of inhaled and oral salbutamol by urine analysis using conventional screening procedures for doping control. Ther. Drug Monit. 22, 277–282.
IOC Medical Commission. (1998), Minutes of meeting Nagano February 1998. Lausanne, Switzerland.
Berges, R., Segura, J., Ventura, R., et al. (2000), Discrimination of prohibited oral use of salbutamol from authorized inhaled asthma treatment. Clin. Chem. 46, 1365–1375.
http://www.wada-ama.org/rtecontent/document/ 2006_LIST.pdf, Accessed January 15, 2006.
Schweizer, C., Saugy, M., and Kamber, M. (2004), Doping test reveals high concentrations of salbutamol in a Swiss track and field athlete. Clin. J. Sport Med. 14, 312–315.
Jacobson, G. A., Peterson, G. M., and McLean, S. (1997), Investigation of urinary levels of salbutamol in asthmatic patients receiving inhaled therapy. J. Clin. Pharm. Ther. 22, 119–126.
Glaxo Smith Kline. (1988), GSK Study GM198/00055/00.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Fitch, K.D. β2-Agonists at the olympic games. Clinic Rev Allerg Immunol 31, 259–268 (2006). https://doi.org/10.1385/CRIAI:31:2:259
Issue Date:
DOI: https://doi.org/10.1385/CRIAI:31:2:259